Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide.
Product Name : ORIC-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2021
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ORIC-101,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ORIC-101 is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 plasma concentrations provided excellen...
Product Name : ORIC-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2021
Lead Product(s) : ORIC-101,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data demonstrate that GR may be a mechanism of resistance to AR degraders and that in vitro, ORIC-101 overcomes GR-driven resistance to AR degradation.
Product Name : ORIC-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 10, 2020
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ORIC-101 overcame GR-mediated resistance to chemotherapeutic agents including taxanes, antimetabolites and platinums, in both in vitro and in vivo efficacy studies spanning a variety of solid tumor types.
Product Name : ORIC-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : J.P. Morgan
Deal Size : $120.0 million
Deal Type : Public Offering
ORIC pulls off $120M Wall Street debut, eclipsing $86M goal
Details : The IPO proceeds will push ORIC Pharma's lead program through phase 1b and into phase 2 and move its second program into the clinic.
Product Name : ORIC-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 23, 2020
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : J.P. Morgan
Deal Size : $120.0 million
Deal Type : Public Offering
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : J.P. Morgan
Deal Size : $75.0 million
Deal Type : Public Offering
Oncology Biotech ORIC Pharmaceuticals Sets Terms for $75 Million IPO
Details : The funding is directed towards company's advancing pipeline of drug candidates for the treatment of prostate cancer and solid tumors.
Product Name : ORIC-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 20, 2020
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : J.P. Morgan
Deal Size : $75.0 million
Deal Type : Public Offering
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study based on preclinical evidence suggesting ORIC-101, may inhibit a potential mechanism of resistance to XTANDI® in patients with metastatic prostate cancer.
Product Name : ORIC-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2020
Lead Product(s) : ORIC-101,Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable